Vanguard Global Advisers
AVTX icon

Vanguard Global Advisers’s Avalo Therapeutics AVTX Stock Holding History

Vanguard Global Advisers’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Buy
20,010
+14,405
+257% +$228K ﹤0.01% 2242
2026
Q1 		$83.7K Buy
+5,605
New +$87.6K ﹤0.01% 2799

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Global Advisers's AVTX Position: Q2 2026 in Review

Vanguard Global Advisers increased its Avalo Therapeutics (AVTX) stake by 257% in Q2 2026, buying an estimated $228K and bringing the position to 20,010 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #2242.

Vanguard Global Advisers first reported a position in AVTX in Q1 2026 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Vanguard Global Advisers held 20,010 shares of Avalo Therapeutics worth $370K as of Q2 2026.
  • Vanguard Global Advisers bought 14,405 Avalo Therapeutics shares in Q2 2026, an estimated $228K.
  • Avalo Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2242 holding.
  • Vanguard Global Advisers first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.